StreetInsider.com News Articles

Form 8-K SANUWAVE Health, Inc. For: Jun 16

Tue, 16 Jun 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26650856.html

Form 8-K SANUWAVE Health, Inc. For: Jun 16

Tue, 16 Jun 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26650856.html

Form 8-K SANUWAVE Health, Inc. For: Jun 16

Tue, 16 Jun 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26650856.html

Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure

Tue, 16 Jun 2026 08:00:46 -0400

Sanuwave Health, Inc. (NASDAQ: SNWV) revised its second-quarter 2026 revenue guidance to a range of $8.5 million to $9.5 million, below the outlook the company provided during its first-quarter earnings call on May 13, 2026.

CEO Morgan Frank attributed the revision to deteriorating conditions in the capital equipment market for the company's Ultramist system. Frank said that while March and April had shown signs of improvement, May and early June brought a reversal of those trends.

Frank cited widespread clawbacks of CMS reimbursement for skin substitutes and allograft usage as a key factor driving wound care practices out of business. He said

Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure

Tue, 16 Jun 2026 08:00:46 -0400

Frank cited widespread clawbacks of CMS reimbursement for skin substitutes and allograft usage as a key factor driving wound care practices out of business. He said

Sanuwave Health Updates Second Quarter 2026 Guidance

Tue, 16 Jun 2026 08:00:00 -0400

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million

Company on pace for record unit sales of applicators in Q2

Market disruption impacting Ultramist system sales

EDEN PRAIRIE, Minn., June 16, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wound care, today announced that revenues for the second quarter of 2026 are expected to be in the range of $8.5 to $9.5 million, below the guidance provided on the Q1 earnings call on May 13

Sanuwave Health Updates Second Quarter 2026 Guidance

Tue, 16 Jun 2026 08:00:00 -0400

Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million

Company on pace for record unit sales of applicators in Q2

Market disruption impacting Ultramist system sales

Form 8-K SANUWAVE Health, Inc. For: Jun 11

Mon, 15 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260615/26648721.html

Form 8-K SANUWAVE Health, Inc. For: Jun 11

Mon, 15 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260615/26648721.html

Form 8-K SANUWAVE Health, Inc. For: Jun 11

Mon, 15 Jun 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260615/26648721.html

Form SD SANUWAVE Health, Inc.

Fri, 29 May 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260529/26576134.html

Form SD SANUWAVE Health, Inc.

Fri, 29 May 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260529/26576134.html

Form SD SANUWAVE Health, Inc.

Fri, 29 May 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260529/26576134.html

Sanuwave Announces Revenues and Financial Results for Q1 FY2026

Tue, 12 May 2026 17:00:00 -0400

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.

Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.

GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025.

Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025

EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the

Sanuwave Announces Revenues and Financial Results for Q1 FY2026

Tue, 12 May 2026 17:00:00 -0400

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.

Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.

GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025.

Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025

EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the

Form 8-K SANUWAVE Health, Inc. For: May 12

Tue, 12 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260512/26478646.html

Form 8-K SANUWAVE Health, Inc. For: May 12

Tue, 12 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260512/26478646.html

Form 8-K SANUWAVE Health, Inc. For: May 12

Tue, 12 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260512/26478646.html

Form 10-Q SANUWAVE Health, Inc. For: Mar 31

Tue, 12 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260512/26478617.html

Form 10-Q SANUWAVE Health, Inc. For: Mar 31

Tue, 12 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260512/26478617.html

Form 10-Q SANUWAVE Health, Inc. For: Mar 31

Tue, 12 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260512/26478617.html

Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results

Wed, 06 May 2026 17:00:00 -0400

EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM (ET) to present its Q1 2026 financial results.

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information

Toll Free: 1-833-316-1983

Toll/International: 1-785-838-9310

Conference ID: SANUWAVE

OR click the link below to access the live webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d7338d6

Materials for the conference

Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results

Wed, 06 May 2026 17:00:00 -0400

Telephone access to the call will be available by dialing the following numbers:

Participant Dial-in Information

Toll Free: 1-833-316-1983

Toll/International: 1-785-838-9310

Conference ID: SANUWAVE

OR click the link below to access the live webcast:
https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d7338d6

Materials for the conference

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: Opaleye Management Inc.

Mon, 04 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260504/26425465.html

Form SCHEDULE 13G/A SANUWAVE Health, Inc. Filed by: Opaleye Management Inc.

Mon, 04 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260504/26425465.html